BCRX
BioCryst Pharmaceuticals, Inc.
4.16
+
0.00
0.00%
14 x 4.14
17 x 4.17
bid
ask
16 @ 04:00 PM
4.16+0.00 (0.00%)
Bearish
30
Bullish
81
sentiment
4.12
day range
4.26
4.16
52 week range
8.81
Prev Close4.16
Open4.21
Low4.12
High4.26
Volume2.22M
Avg. Volume3.16M
Market Cap857.58M
Inst. Own87.99%
Beta1.93
Short Ratio9.91
Div & Yield0.00 /
EPS-1.18
P/E0.00
1yr Target13.82
50day MA5.11
200day MA6.03
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Profile
...
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-05-06 | 2024-03 | -0.23 | N/A | N/A | N/A |
2024-02-26 | 2023-12 | -0.24 | -0.28 | -0.04 | -16.67% |
2023-11-02 | 2023-09 | -0.25 | -0.19 | 0.06 | 24.00% |
2023-08-03 | 2023-06 | -0.25 | -0.24 | 0.01 | 4.00% |
2023-05-03 | 2023-03 | -0.3 | -0.28 | 0.02 | 6.67% |
2023-02-21 | 2022-12 | -0.19 | -0.38 | -0.19 | -100.00% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-24 | RBC Capital | Upgrade | Outperform | Outperform |
2023-09-17 | RBC Capital | Upgrade | Sector Perform | Outperform |
2023-08-03 | RBC Capital | Upgrade | Sector Perform | Sector Perform |
2023-08-03 | Jefferies | Upgrade | Hold | Buy |
2023-08-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-02 | Needham | Upgrade | Buy |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2023-12-13 | BARNES ALANE P | Officer | 296.02K | Stock Award(Grant) |
2023-12-13 | DOYLE ANTHONY | Chief Financial Officer | 229.93K | Stock Award(Grant) |
2023-12-13 | GAYER CHARLES K | Officer | 277.02K | Stock Award(Grant) |
2024-02-28 | HEGGIE THERESA | Director | 51.86K | Stock Award(Grant) |
2023-06-13 | HUTSON NANCY J | Director | 81.82K | Sale |
2023-06-12 | LEVIN ALAN G | Director | 37.09K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 15.50M | 109.09M | 8.18% |
2023-06-29 | Vanguard Group Inc | 15.09M | 106.23M | 7.96% |
2023-06-29 | Baker Brothers Advisors, LLC | 12.71M | 89.48M | 6.71% |
2023-06-29 | State Street Corporation | 12.26M | 86.34M | 6.47% |
2023-06-29 | Avoro Capital Advisors LLC | 12.06M | 84.87M | 6.36% |
2023-06-29 | Assenagon Asset Management S.A. | 5.33M | 37.54M | 2.81% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-08-30 | SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF | 8.22M | 58.41M | 4.34% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 5.86M | 41.26M | 3.09% |
2023-08-30 | iShares Russell 2000 ETF | 4.29M | 30.51M | 2.26% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 2.81M | 19.96M | 1.48% |
2023-06-29 | Vanguard Extended Market Index Fund | 2.58M | 18.14M | 1.36% |
2023-06-29 | Vanguard Small-Cap Index Fund | 2.44M | 17.17M | 1.29% |
Dividend
...
Dividend | Date |
---|---|
0 | 2014-06-11 |
0 | 2014-06-05 |
0 | 2014-05-20 |
0 | 2014-05-16 |
0 | 2014-04-02 |
This topic has been deleted. Only users with topic management privileges can see it.
-
-
-
IBIO EVENTS :IPF Summit Digital August 24-26, 2020 ,Online Event, KC Animal Heath Summit,August 31 – September 2, 2020. Just remember that IBIO and fast farming was created to make vaccine very fast in case of a pandemic,now this COVID-19 virusu is all over the world,other companies will stay in line to get a contract with IBIO, do to their fast farming,contracts with IBIO will happen very soon in the future and this stock will skyrocket
-
-
$BCRX - End of the road for the shorts
-
$BCRX - Short holders, better look at that
https://twitter.com/shmulic12/status/1296151778853941248?s=21
-
$BCRX - area of 4.3-4.5 is the end of the line for short holders.
-
$BCRX - Trigger was set to 4.66
https://twitter.com/shmulic12/status/1295795067567792128?s=21
-
-
-
-
-
-
-
-
BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 12-Month Low at $4.15
news.google.com • -
BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 12-Month Low at $4.15
news.google.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report Third Quarter 2023 Financial Results on November 2
globenewswire.com • -
BioCryst Pharmaceuticals rallies on Quebec reimbursement for Orladeyo angioedema treatment
proactiveinvestors.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2023 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Second Quarter 2023 Financial Results on August 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst to Report First Quarter 2023 Financial Results on May 3
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst: Good Candidate For Buyout, But Not For Anything Else
seekingalpha.com • -
BioCryst Is Not Currently Uncovering The Full Value Of ORLADEYO
seekingalpha.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Fourth Quarter 2022 Financial Results on February 21
globenewswire.com • -
Pharmaceutical Stock Sinks on Sales Forecast
schaeffersresearch.com • -
BioCryst to Present at 41st Annual J.P. Morgan Healthcare Conference
globenewswire.com • -
BioCryst Pharmaceuticals: More Aggressive Growth For Orladeyo
seekingalpha.com • -
BCRX Stock Sinks as BioCryst Discontinues Drug Development
investorplace.com • -
BioCryst to discontinue development of drug
marketwatch.com • -
BioCryst to Present at JMP Securities Hematology & Oncology Summit
globenewswire.com • -
3 Biotechnology stocks under 10 dollars to buy now
thedogofwallstreet.com • -
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
BioCryst to Report Third Quarter 2022 Financial Results on November 1
globenewswire.com • -
3 Biotech Stocks to Buy Now for Extraordinary Gains
investorplace.com • -
Options Bulls Blast Phama Stock on Lifted Clinical Hold
schaeffersresearch.com • -
3 Fast-Growing Stocks to Buy Now
fool.com • -
BioCryst to Report Second Quarter 2022 Financial Results on August 4
globenewswire.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
BioCryst: A Prudent Diversification
seekingalpha.com • -
7 Cheap Biotech Stocks to Buy Now
investorplace.com • -
BioCryst to Present at Upcoming Investor Conferences
globenewswire.com • -
BioCryst to Report First Quarter 2022 Financial Results on May 5
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Falling
benzinga.com • -
BioCryst to Present at Upcoming Investor Conference
globenewswire.com • -
Why BioCryst Pharmaceuticals Stock Is Plunging Today
benzinga.com • -
BioCryst Provides Tremendous Option Value
seekingalpha.com • -
BioCryst: Great Execution, Impressive Pipeline, Long Cash Runway
seekingalpha.com • -
7 Top Growth Stocks to Buy as We Step Into November
investorplace.com • -
BioCryst to Report Third Quarter 2021 Financial Results on November 3
globenewswire.com • -
7 Best Growth Stocks to Buy and Hold for the Next 10 Years
investorplace.com • -
2 Super-Charged Growth Stocks to Buy Now
fool.com • -
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
NICE Recommends BioCryst's Hereditary Angioedema Med
benzinga.com •